# Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

> **NCT07671092** · EARLY_PHASE1 · RECRUITING · sponsor: **RayzeBio, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Metastatic Urothelial Carcinoma
- Breast Cancer
- TNBC - Triple-Negative Breast Cancer
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- NSCLC

## Interventions

- **DIAGNOSTIC_TEST:** RYZ211/212

## Key facts

- **NCT ID:** NCT07671092
- **Lead sponsor:** RayzeBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2027-08
- **Final completion:** 2027-11
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07671092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07671092, "Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07671092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*